BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17971592)

  • 1. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
    Chi DS; Ramirez PT; Teitcher JB; Mironov S; Sarasohn DM; Iyer RB; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Brown CL; Aghajanian C; Gershenson DM; Hoskins WJ; Hricak H; Barakat RR
    J Clin Oncol; 2007 Nov; 25(31):4946-51. PubMed ID: 17971592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
    Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
    Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
    Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
    Chi DS; Zivanovic O; Levinson KL; Kolev V; Huh J; Dottino J; Gardner GJ; Leitao MM; Levine DA; Sonoda Y; Abu-Rustum NR; Brown CL; Barakat RR
    Gynecol Oncol; 2010 Oct; 119(1):38-42. PubMed ID: 20609464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
    Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Eskander RN; Kauderer J; Tewari KS; Mannel RS; Bristow RE; O'Malley DM; Rubin SC; Glaser GE; Hamilton CA; Fujiwara K; Huh WK; Ueland F; Stephan JM; Burger RA
    Gynecol Oncol; 2018 Jun; 149(3):525-530. PubMed ID: 29550184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer.
    Kehoe SM; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; D'Angelica M; Jarnagin WR; Barakat RR; Chi DS
    Gynecol Oncol; 2009 Mar; 112(3):496-500. PubMed ID: 19091388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.
    Black D; Iasonos A; Ahmed H; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2007 Oct; 107(1):66-70. PubMed ID: 17614125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
    Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
    AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Mironov S; Iyer RB; Zhou Q; Iasonos A; Paul H; Hosaka M; Aghajanian CA; Leitao MM; Gardner GJ; Abu-Rustum NR; Sonoda Y; Levine DA; Hricak H; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):455-61. PubMed ID: 25019568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer.
    Bashir S; Gerardi MA; Giuntoli RL; Montes TP; Bristow RE
    Gynecol Oncol; 2010 Nov; 119(2):255-8. PubMed ID: 20739051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.
    Abu-Rustum NR; Richard S; Wilton A; Lev G; Sonoda Y; Hensley ML; Gemignani M; Barakat RR; Chi DS
    Gynecol Oncol; 2005 Nov; 99(2):320-6. PubMed ID: 16061278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions.
    Juretzka MM; Abu-Rustum NR; Sonoda Y; Downey RJ; Flores RM; Park BJ; Hensley ML; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Mar; 104(3):670-4. PubMed ID: 17150248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.